united states , fail to either complete treatment or show a long-term sustained response to therapy .as a result , we believe new safe and effective treatment options for hcv infection are needed .telaprevir development program we are conducting three major phase 2b clinical trials of telaprevir .prove 1 is ongoing in the united states and prove 2 is ongoing in european union , both in treatment-na efve patients .prove 3 has commenced and is being conducted with patients in north america and the european union who did not achieve sustained viral response with previous interferon-based treatments .prove 1 and prove 2 are fully enrolled , and we commenced patient enrollment in prove 3 in january 2007 .prove 1 and prove 2 we expect that together , the prove 1 and prove 2 clinical trials will evaluate rates of sustained viral response , or svr , in approximately 580 treatment-na efve patients infected with genotype 1 hcv , including patients who will receive telaprevir and patients in the control arms .svr is defined as undetectable viral levels 24 weeks after all treatment has ceased .a description of each of the clinical trial arms for the prove 1 and prove 2 clinical trials , including the intended number of patients in each trial , is set forth in the following table : the prove 1 and prove 2 clinical trials together have the following four key objectives : 2022 to evaluate the optimal svr rate that can be achieved with telaprevir therapy in combination with peg-ifn and rbv ; 2022 to evaluate the optimal treatment duration for telaprevir combination therapy ; 2022 to evaluate the role of rbv in telaprevir-based therapy ; and 2022 to evaluate the safety of telaprevir in combination with peg-ifn and rbv .in the prove 1 and prove 2 clinical trials , patients receive telaprevir in a tablet formulation at a dose of 750 mg every eight hours for 12 weeks .the prove 1 clinical trial is double-blinded and placebo-controlled , and the prove 2 clinical trial is partially-blinded and placebo-controlled .in december 2006 , we announced results from a planned interim safety and antiviral activity analysis that was conducted and reviewed by the independent data monitoring committee overseeing the prove 1 clinical trial .as of the cut-off date of the interim analysis , a total of 250 patients had been enrolled in the prove 1 clinical trial and received at least one dose of telaprevir or placebo .in the data reported , the patients in all three telaprevir-containing arms ( approximately 175 patients ) were pooled together and the results were compared to the results in the control arm of peg-ifn and rbv and placebo ( approximately 75 patients ) .at the time of the data cut-off for the safety analysis , approximately 100 patients had completed 12 weeks on-study and more than 200 patients had completed eight weeks .the most common adverse treatment regimen number of patients ( treatment na efve ) prove 1 number of patients ( treatment na efve ) prove 2 total .
[['treatment regimen', 'number of patients ( treatment na efve ) prove 1', 'number of patients ( treatment na efve ) prove 2', 'total'], ['12-week regimens of telaprevir in combination with peg-ifn and rbv', '20', '80', '100'], ['12-week regimens of telaprevir in combination with only peg-ifn', '0', '80', '80'], ['12-week regimens of telaprevir in combination with peg-ifn and rbv followed by 12 weeks of therapy with peg-ifn and rbv', '80', '80', '160'], ['12-week regimens of telaprevir in combination with peg-ifn and rbv followed by 36 weeks of therapy with peg-ifn and rbv', '80', '0', '80'], ['48-weeks of therapy with peg-ifn and rbv', '80', '80', '160'], ['total', '260', '320', '580']]
.

Question: what was the percent of the total treatment regiment for prove1 for the 48-weeks of therapy with peg-ifn and rbv
Answer: 30.8%